---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-007007"
form_type: "8-K"
ticker: "CBDW"
cik: "0001877461"
company_name: "1606 CORP."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:16:55.223192+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 1606 Corp. target Adnexus merges with Sanctum for HIV and COVID-19 assets

## Summary
- Adnexus Biotechnologies completed acquisition of Sanctum Therapeutics' core tech assets for HIV and SARS-CoV-2.
- Combines Adnexus AI drug discovery platform with Sanctum's long-acting HIV capsid inhibitor and monoclonal antibodies.
- 1606 Corp. has a letter of intent for a 5% equity stake in Adnexus; LOI expires November 27, 2024.
- CEO Austen Lambrecht calls merger a pivotal moment in fighting infectious diseases.

## SEC filing metadata
- accession: 0001477932-24-007007
- form_type: 8-K
- ticker: CBDW
- cik: 0001877461
- company_name: 1606 CORP.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1877461/000147793224007007/0001477932-24-007007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1877461/000147793224007007/cbdw_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-007007
- JSON: https://secwatch.observer/filing/0001477932-24-007007.json
- Plain text: https://secwatch.observer/filing/0001477932-24-007007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.